CONNECT WITH US
HealthTech

HealthTech

Commonly mutated gene could be a therapeutic target in sarcoma

Medical Xpress logo

Published on

Add as a preferred source on Google
Commonly mutated gene could be a therapeutic target in sarcoma

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors. The findings identify ATRX loss as both a marker of poor prognosis and a potential therapeutic target.

The study, published in The Journal of Clinical Investigation, was led by Kunal Rai, Ph.D., professor of genomic medicine. If validated in future clinical trials, the results suggest ATRX—one of the most commonly mutated genes in sarcoma—could be a potential biomarker to guide treatment selection for patients with soft-tissue sarcomas.

"For many patients with sarcoma, treatment decisions still are not guided by the biology of their tumors," Rai said. "We found that ATRX loss may identify patients who are more likely to benefit from TEAD inhibitors, creating a potential path toward precision medicine for these difficult-to-treat cancers."

Sarcomas are rare cancers with limited treatment options, particularly when the disease spreads. While ATRX is one of the most frequently altered genes in several sarcoma subtypes, researchers have not understood how these alterations influence patient outcomes or whether they could be targeted therapeutically.

The ATRX protein normally works to help organize chromatin, the tightly packed complex of DNA and proteins that forms chromosomes. To better understand the role of ATRX alterations in sarcoma, researchers evaluated tumor samples from patients with soft tissue and uterine leiomyosarcoma, undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.